Health Care [ 2/12 ] | Biotechnology [ 10/75 ]
NASDAQ | Common Stock
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates.
The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement.
Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 12, 26 | -0.05 Increased by +50.00% | 0.00 Decreased by -2.60 K% |
| Nov 10, 25 | 0.00 Increased by +102.00% | -0.04 Increased by +105.00% |
| Aug 7, 25 | 0.03 Increased by +166.75% | -0.02 Increased by +233.50% |
| May 7, 25 | 0.02 Increased by +127.44% | -0.08 Increased by +130.88% |
| Mar 12, 25 | -0.10 Decreased by -3.23 K% | -0.07 Decreased by -33.33% |
| Nov 6, 24 | -0.10 Decreased by -25.00% | -0.06 Decreased by -66.67% |
| Aug 8, 24 | -0.04 Increased by +33.33% | -0.05 Increased by +20.00% |
| May 9, 24 | -0.09 Increased by +35.71% | -0.08 Decreased by -12.50% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 57.62 M Increased by +23.92% | -12.24 M Increased by +46.31% | Decreased by -21.25% Increased by +56.67% |
| Sep 30, 25 | 58.77 M Increased by +57.01% | 540.00 K Increased by +102.69% | Increased by +0.92% Increased by +101.72% |
| Jun 30, 25 | 62.47 M Increased by +43.13% | 247.00 K Increased by +102.88% | Increased by +0.40% Increased by +102.01% |
| Mar 31, 25 | 57.34 M Increased by +75.84% | 6.11 M Increased by +133.98% | Increased by +10.66% Increased by +119.33% |
| Dec 31, 24 | 46.50 M Decreased by -17.26% | -22.80 M Decreased by -3.81 K% | Decreased by -49.04% Decreased by -4.59 K% |
| Sep 30, 24 | 37.43 M Decreased by -10.98% | -20.04 M Decreased by -38.30% | Decreased by -53.54% Decreased by -55.37% |
| Jun 30, 24 | 43.65 M Decreased by -22.58% | -8.58 M Increased by +23.18% | Decreased by -19.66% Increased by +0.78% |
| Mar 31, 24 | 32.61 M Decreased by -18.49% | -17.98 M Increased by +33.08% | Decreased by -55.16% Increased by +17.90% |